Biosimulation can mitigate risk of COVID-19 drug development Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation -- using computers to simulate drug response in humans -- can help accelerate the process, which Certara hopes to achieve with a new platform launched today targeted at COVID-19 vaccine development. Discuss
Bruker supports COVID19-NMR Consortium Bruker is highlighting its support of a global project called COVID19-NMR that will investigate the structure, dynamics, function, and binding of SARS-CoV-2 viral RNA and proteins using nuclear magnetic resonance (NMR) spectroscopy.
Illumina's Q2 revenue drops 25% Illumina's revenue dropped 25% due to the impact of the COVID-19 pandemic on the company's business in the second quarter. The company's net income also dropped sharply.
Gum disease may affect COVID-19 severity Patients with inflammation caused by periodontitis may experience more severe COVID-19 complications, according to an article published online July 30 in the Journal of the California Dental Association. Discuss
Pfizer to manufacture remdesivir for Gilead Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other external manufacturing organizations in supporting efforts to scale up supply for the treatment of COVID-19.
CROs offer new COVID-19 services Contract research organizations (CROs) Caprion-HistoGeneX and Viroclinics have formed a strategic partnership to develop therapeutics and prophylactic solutions targeting infectious diseases like COVID-19.